Whalegun
Lobbying

Novo Nordisk A/S NVO's latest lobbying report covers Q2 2026, at under $5,000. Its first report covers Q2 2024; the issues it reports most are Health Issues and Manufacturing.

Novo Nordisk A/SNVO

Novo Nordisk A/S stock page

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$0
Last 4 quarters
vs last quarter
No record
Q3 2026 against the quarter before
First report
Q2 2024
The first quarter a report named it

Lobbying by quarter

Novo Nordisk A/S lobbying by quarter
Novo Nordisk A/S lobbying by quarter
QuarterAmountReports
Q2 2024$20K1
Q3 2024$01
Q4 2024$10K1
Q1 2025$01
Q2 2025$01
Q3 2025$01
Q4 2025$01
Q1 2026$01
Q2 2026$01
Q3 2026$00

By issue

  • Health issues$15K · 4 reports
  • Manufacturing$15K · 4 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • HOUSE OF REPRESENTATIVES4 reports
  • SENATE4 reports

Firms it paid

Firm
Arnold & Porter Kaye Scholer$30K9 quarters

Former officials lobbying for it

Former position
LUKE ALBERTIntern, Rep. Kendra Horn (2019)Q2 2024
MICKAYLA STOGSDILLIntern, Senate Health, Education, Labor, and Pensions Committee (2018)Q2 2024
PETER ERIC DUYSHARTProgram Support Student Trainee, Secretarial Internship Program, U.S. DOT (2020); Intern, Rep. Karen Bass (2015-2016); Extern, U.S. Attorneys Office, Central District of California (2015)Q2 2024

Lobbying reports

Filed by
07/17for Q2Arnold & Porter Kaye ScholerUnder $5,000
04/17for Q1Arnold & Porter Kaye ScholerUnder $5,000
01/14for Q4 2025Arnold & Porter Kaye ScholerUnder $5,000
25/10/15for Q3 2025Arnold & Porter Kaye ScholerUnder $5,000
25/07/17for Q2 2025Arnold & Porter Kaye ScholerUnder $5,000
25/04/17for Q1 2025Arnold & Porter Kaye ScholerUnder $5,000
25/01/16for Q4 2024Arnold & Porter Kaye Scholer$10K
24/10/17for Q3 2024Arnold & Porter Kaye ScholerUnder $5,000
24/07/19for Q2 2024Arnold & Porter Kaye Scholer$20K
24/05/28for Q2 2024Arnold & Porter Kaye ScholerUnder $5,000